Signal transduction of the CB1 cannabinoid receptor

Journal of Molecular Endocrinology

Volumn 44, Issue 2, 2010, Pages 75-85

  Turu, Gábor ^a   Hunyady, László ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; BETA ARRESTIN; CANNABINOID 1 RECEPTOR; CANNABIS; CYCLIC AMP; ENDOCANNABINOID; GUANINE NUCLEOTIDE BINDING PROTEIN; ION CHANNEL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NUCLEAR FACTOR Y; OLIGOMER; PHOSPHOLIPASE; POTASSIUM CHANNEL; RIMONABANT; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR;

DEPOLARIZATION; DRUG ACTIVITY; ENDOCRINE CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; NEUROMODULATION; NEUROTRANSMISSION; OBESITY; PHOSPHORYLATION; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TOBACCO DEPENDENCE; ANIMAL; METABOLISM;

ANIMALS; HUMANS; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION;

EID: 75749126604     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1677/JME-08-0190     Document Type: Review

References (124)

1. s. Journal of Neurochemistry 72 2032-2038.
2. Adan RA & Kas MJ 2003 Inverse agonism gains weight. Trends in Pharmacological Sciences 24 315-321.
3. Azad SC, Kurz J, Marsicano G, Lutz B, Zieglgansberger W & Rammes G 2008 Activation of CB1 specifically located on GABAergic interneurons inhibits LTD in the lateral amygdala. Learning and Memory 15 143-152.
4. Baker D, Pryce G, Davies WL & Hiley CR 2006 In silico patent searching reveals a new cannabinoid receptor. Trends in Pharmacological Sciences 27 1-4.
5. Bellocchio L, Mancini G, Vicennati V, Pasquali R & Pagotto U 2006 Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Current Opinion in Pharmacology 6 586-591.
6. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ et al. 2003 Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signalling in the brain. Journal of Cell Biology 163 463-468.
7. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J et al. 1997 A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. Journal of Biological Chemistry 272 22330-22339.
8. Breivogel CS & Childers SR 2000 Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. Journal of Pharmacology and Experimental Therapeutics 295 328-336.
9. Breivogel CS, Sim LJ & Childers SR 1997 Regional differences in cannabinoid receptor/G-protein coupling in rat brain. Journal of Pharmacology and Experimental Therapeutics 282 1632-1642.
10. Breivogel CS, Walker JM, Huang SM, Roy MB & Childers SR 2004 Cannabinoid signalling in rat cerebellar granule cells: G-protein activation, inhibition of glutamate release and endogenous cannabinoids. Neuropharmacology 47 81-91.
11. Breivogel CS, Lambert JM, Gerfin S, Huffman JW & Razdan RK 2008 Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2 - / - mice. Behavioural Pharmacology 19 298-307.
12. Brown SP, Safo PK & Regehr WG 2004 Endocannabinoids inhibit transmission at granule cell to Purkinje cell synapses by modulating three types of presynaptic calcium channels. Journal of Neuroscience 24 5623-5631.
13. Bulenger S, Marullo S & Bouvier M 2005 Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends in Pharmacological Sciences 26 131-137.
14. Calandra B, Portier M, Kerneis A, Delpech M, Carillon C, Le Fur G, Ferrara P & Shire D 1999 Dual intracellular signalling pathways mediated by the human cannabinoid CB1 receptor. European Journal of Pharmacology 374 445-455.
15. Canals M & Milligan G 2008 Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed μ opioid receptors. Journal of Biological Chemistry 283 11424-11434.
16. Carriba P, Navarro G, Ciruela F, Ferre S, Casado V, Agnati L, Cortes A, Mallol J, Fuxe K, Canela EI et al. 2008 Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nature Methods 5 727-733.
17. Caulfield MP & Brown DA 1992 Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. British Journal of Pharmacology 106 231-232.
18. Chillakuri CR, Reinhart C & Michel H 2007 C-terminal truncated cannabinoid receptor 1 coexpressed with G protein trimer in Sf9 cells exists in a precoupled state and shows constitutive activity. FEBS J 274 6106-6115.
19. Chevaleyre V & Castillo PE 2003 Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron 38 461-472.
20. Cinar R, Freund TF, Katona I, Mackie K & Szucs M 2008 Reciprocal inhibition of G-protein signalling is induced by CB(1) cannabinoid and GABA(B) receptor interactions in rat hippocampal membranes. Neurochemistry International 52 1402-1409.
21. Daigle TL, Kearn CS & Mackie K 2008a Rapid CB(1) cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signalling. Neuropharmacology 54 36-44.
22. Daigle TL, Kwok ML & Mackie K 2008b Regulation of CB1 cannabinoid receptor internalization by a promiscuous phosphorylation-dependent mechanism. Journal of Neurochemistry 106 70-82.
23. Davis MI, Ronesi J & Lovinger DM 2003 A predominant role for inhibition of the adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells. Journal of Biological Chemistry 278 48973-48980.
24. Derkinderen P, Ledent C, Parmentier M & Girault JA 2001 Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. Journal of Neurochemistry 77 957-960.
25. Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C, Trzaskos J, Caboche J & Girault JA 2003 Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. Journal of Neuroscience 23 2371-2382.
26. Devane WA, Dysarz FA III, Johnson MR, Melvin LS & Howlett AC 1988 Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology 34 605-613.
27. Downer EJ, Fogarty MP & Campbell VA 2003 Tetrahydrocannabinol-induced neurotoxicity depends on CB1 receptor-mediated c-Jun N-terminal kinase activation in cultured cortical neurons. British Journal of Pharmacology 140 547-557.
28. Downer EJ, Gowran A & Campbell VA 2007 A comparison of the apoptotic effect of Δ(9)-tetrahydrocannabinol in the neonatal and adult rat cerebral cortex. Brain Research 1175 39-47.
29. Ellis J, Pediani JD, Canals M, Milasta S & Milligan G 2006 Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. Journal of Biological Chemistry 281 38812-38824.
30. Endoh T 2006 Pharmacological characterization of inhibitory effects of postsynaptic opioid and cannabinoid receptors on calcium currents in neonatal rat nucleus tractus solitarius. British Journal of Pharmacology 147 391-401.
31. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K & Devane WA 1993 Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. PNAS 90 7656-7660.
32. Fisyunov A, Tsintsadze V, Min R, Burnashev N & Lozovaya N 2006 Cannabinoids modulate the P-type high-voltage-activated calcium currents in purkinje neurons. Journal of Neurophysiology 96 1267-1277.
33. Freund TF, Katona I & Piomelli D 2003 Role of endogenous cannabinoids in synaptic signalling. Physiological Reviews 83 1017-1066.
34. Galve-Roperh I, Rueda D, Gomez DP, Velasco G & Guzman M 2002 Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Molecular Pharmacology 62 1385-1392.
35. Galvez T, Duthey B, Kniazeff J, Blahos J, Rovelli G, Bettler B, Prezeau L & Pin JP 2001 Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function. EMBO Journal 20 2152-2159.
36. Gaoni YMR 1964 Isolation, structure, and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society 86 1646-1647.
37. Gardner A & Mallet PE 2006 Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. European Journal of Pharmacology 530 103-106.
38. 2+ channel current. American Journal of Physiology 276 H2085-H2093.
39. Georgieva T, Devanathan S, Stropova D, Park CK, Salamon Z, Tollin G, Hruby VJ, Roeske WR, Yamamura HI & Varga E 2008 Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signalling. European Journal of Pharmacology 581 19-29.
40. s linkage to the CB1 receptor. Journal of Neuroscience 17 5327-5333.
41. Glass M & Northup JK 1999 Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Molecular Pharmacology 56 1362-1369.
42. Graham ES, Ball N, Scotter EL, Narayan P, Dragunow M & Glass M 2006 Induction of Krox-24 by endogenous cannabinoid type 1 receptors in Neuro2A cells is mediated by the MEK-ERK MAPK pathway and is suppressed by the phosphatidylinositol 3-kinase pathway. Journal of Biological Chemistry 281 29085-29095.
43. Guo J & Ikeda SR 2004 Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. Molecular Pharmacology 65 665-674.
44. Hampson AJ, Bornheim LM, Scanziani M, Yost CS, Gray AT, Hansen BM, Leonoudakis DJ & Bickler PE 1998 Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. Journal of Neurochemistry 70 671-676.
45. He JC, Gomes I, Nguyen T, Jayaram G, Ram PT, Devi LA & Iyengar R 2005 The G alpha(o/i)-coupled cannabinoid receptor-mediated neurite outgrowth involves Rap regulation of Src and Stat3. Journal of Biological Chemistry 280 33426-33434.
46. o/i signalling network in the regulation of neurite outgrowth. Canadian Journal of Physiology and Pharmacology 84 687-694.
47. Henry DJ & Chavkin C 1995 Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neuroscience Letters 186 91-94.
48. Hentges ST, Low MJ & Williams JT 2005 Differential regulation of synaptic inputs by constitutively released endocannabinoids and exogenous cannabinoids. Journal of Neuroscience 25 9746-9751.
49. Hilairet S, Bouaboula M, Carriere D, Le Fur G & Casellas P 2003 Hypersensitization of the orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. Journal of Biological Chemistry 278 23731-23737.
50. Ho BY, Stadnicka A, Prather PL, Buckley AR, Current LL, Bosnjak ZJ & Kwok WM 2000 Cannabinoid CB1 receptor-mediated inhibition of prolactin release and signalling mechanisms in GH4C1 cells. Endocrinology 141 1675-1685.
51. Hoffman AF & Lupica CR 2000 Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. Journal of Neuroscience 20 2470-2479.
52. Hojo M, Sudo Y, Ando Y, Minami K, Takada M, Matsubara T, Kanaide M, Taniyama K, Sumikawa K & Uezono Y 2008 μ-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRETassay analysis. Journal of Pharmacological Sciences 108 308-319.
53. Houston DB & Howlett AC 1998 Differential receptor-G-protein coupling evoked by dissimilar cannabinoid receptor agonists. Cellular Signalling 10 667-674.
54. Howlett AC 1985 Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Molecular Pharmacology 27 429-436.
55. Howlett AC 2005 Cannabinoid receptor signalling. Handbook of Experimental Pharmacology 168 53-79.
56. Howlett AC & Fleming RM 1984 Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Molecular Pharmacology 26 532-538.
57. i in the inhibition of adenylate cyclase by cannabimimetic drugs. Molecular Pharmacology 29 307-313.
58. Jin W, Brown S, Roche JP, Hsieh C, Celver JP, Kovoor A, Chavkin C & Mackie K 1999 Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. Journal of Neuroscience 19 3773-3780.
59. Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, Riddick M, Dowell S, Staton PC, Green P et al. 2007 The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. British Journal of Pharmacology 152 825-831.
60. Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K & Freund TF 1999 Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. Journal of Neuroscience 19 4544-4558.
61. Kearn CS, Blake-Palmer K, Daniel E, Mackie K & Glass M 2005 Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Molecular Pharmacology 67 1697-1704.
62. Kenakin T 2007 Functional selectivity through protean and biased agonism: who steers the ship? Molecular Pharmacology 72 1393-1401.
63. Korzh A, Keren O, Gafni M, Bar-Josef H & Sarne Y 2008 Modulation of extracellular signal-regulated kinase (ERK) by opioid and cannabinoid receptors that are expressed in the same cell. Brain Research 1189 23-32.
64. Kouznetsova M, Kelley B, Shen M & Thayer SA 2002 Desensitization of cannabinoid-mediated presynaptic inhibition of neurotransmission between rat hippocampal neurons in culture. Molecular Pharmacology 61 477-485.
65. Kunos G, Osei-Hyiaman D, Batkai S, Sharkey KA & Makriyannis A 2008 Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends in Pharmacological Sciences 30 1-7.
66. q/11 G proteins. PNAS 102 19144-19149.
67. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B & Mackie K 2008 GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. PNAS 105 2699-2704.
68. Limbird LE & Lefkowitz RJ 1976 Negative cooperativity among beta-adrenergic receptors in frog erythrocyte membranes. Journal of Biological Chemistry 251 5007-5014.
69. Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A & Kunos G 2000 Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochemical Journal 346 835-840.
70. Mackie K & Hille B 1992 Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. PNAS 89 3825-3829.
71. Mackie K, Devane WA & Hille B 1993 Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Molecular Pharmacology 44 498-503.
72. Mackie K, Lai Y, Westenbroek R & Mitchell R 1995 Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. Journal of Neuroscience 15 6552-6561.
73. MacLennan SJ, Reynen PH, Kwan J & Bonhaus DW 1998 Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. British Journal of Pharmacology 124 619-622.
74. Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I, Tanganelli S, Muller CE, Fisone G, Lluis C et al. 2008 Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology 54 815-823.
75. Martin B, Stevenson LA, Pertwee RG, Breivogel CS, Williams W, Mahadevan A & Razdan RK 2002 Agonists and silent antagonists in a series of cannabinoid sulfonamides. Symposium on the Cannabinoids. Burlington, Vermont, International Cannabinoid Research Society, 2.
76. Martin BR, Razdan RK & Pertwee RG 2005 Sulfonamide cannabinoid agonists and antagonists. United States Patent 7279500.
77. Marullo S & Bouvier M 2007 Resonance energy transfer approaches in molecular pharmacology and beyond. Trends in Pharmacological Sciences 28 362-365.
78. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC & Bonner TI 1990 Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 561-564.
79. McAllister SD, Griffin G, Satin LS & Abood ME 1999 Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a Xenopus oocyte expression system. Journal of Pharmacology and Experimental Therapeutics 291 618-626.
80. McPartland JM, Glass M & Pertwee RG 2007 Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. British Journal of Pharmacology 152 583-593.
81. Milligan G & Smith NJ 2007 Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends in Pharmacological Sciences 28 615-620.
82. Milligan G, Canals M, Pediani JD, Ellis J & Lopez-Gimenez JF 2006 The role of GPCR dimerisation/oligomerisation in receptor signalling. Ernst Schering Foundation Symposium Proceedings 2 145-161.
83. Molina-Holgado F, Pinteaux E, Heenan L, Moore JD, Rothwell NJ & Gibson RM 2005 Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signalling. Molecular and Cellular Neurosciences 28 189-194.
84. i protein interactions. Molecular Pharmacology 67 2016-2024.
85. Mukhopadhyay S, McIntosh HH, Houston DB & Howlett AC 2000 The CB(1) cannabinoid receptor juxtamembrane C-terminal peptide confers activation to specific G proteins in brain. Molecular Pharmacology 57 162-170.
86. Mukhopadhyay S, Shim JY, Assi AA, Norford D & Howlett AC 2002 CB(1) cannabinoid receptor-G protein association: a possible mechanism for differential signalling. Chemistry and Physics of Lipids 121 91-109.
87. Munro S, Thomas KL & Abu-Shaar M 1993 Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 61-65.
88. Neu A, Foldy C & Soltesz I 2007 Postsynaptic origin of CB1-dependent tonic inhibition of GABA release at CCK-positive basket cell to pyramidal cell synapses in the CA1 region of the rat hippocampus. Journal of Physiology 578 233-247.
89. Nie J & Lewis DL 2001 Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration. Journal of Neuroscience 21 8758-8764.
90. Oka S, Nakajima K, Yamashita A, Kishimoto S & Sugiura T 2007 Identification of GPR55 as a lysophosphatidylinositol receptor. Biochemical and Biophysical Research Communications 362 928-934.
91. Pacher P, Batkai S & Kunos G 2006 The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews 58 389-462.
92. 2+ channels in a neuronal expression system. Molecular Pharmacology 49 707-714.
93. Paradisi A, Pasquariello N, Barcaroli D & Maccarrone M 2008 Anandamide regulates keratinocyte differentiation by inducing DNA methylation in a CB1 receptor-dependent manner. Journal of Biological Chemistry 283 6005-6012.
94. Pertwee RG 2005 Inverse agonism and neutral antagonism at cannabinoid CBI receptors. Life Sciences 76 1307-1324.
95. De Petrocellis L, Marini P,Matias I, Moriello AS, Starowicz K, Cristino L, Nigam S & Di Marzo M 2007 Mechanisms for the coupling of cannabinoid receptors to intracellular calcium mobilization in rat insulinoma beta-cells. Experimental Cell Research 313 2993-3004.
96. Prather PL, Martin NA, Breivogel CS & Childers SR 2000 Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies. Molecular Pharmacology 57 1000-1010.
97. Rajesh M, Mukhopadhyay P, Hasko G & Pacher P 2008 Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation. Biochemical and Biophysical Research Communications 377 1248-1252.
98. Rhee MH, Bayewitch M, Avidor-Reiss T, Levy R & Vogel Z 1998 Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. Journal of Neurochemistry 71 1525-1534.
99. Rinaldi-Carmona M, Le Duigou A, Oustric D, Barth F, Bouaboula M, Carayon P, Casellas P & Le Fur G 1998 Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. Journal of Pharmacology and Experimental Therapeutics 287 1038-1047.
100. Rios C, Gomes I & Devi LA 2006 m opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signalling and neuritogenesis. British Journal of Pharmacology 148 387-395.
101. Ross RA 2009 The enigmatic pharmacology of GPR55. Trends in Pharmacological Sciences 30 156-163.
102. Rubovitch V, Gafni M & Sarne Y 2002 The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. Brain Research. Molecular Brain Research 101 93-102.
103. Rueda D, Galve-Roperh I, Haro A & Guzman M 2000 The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Molecular Pharmacology 58 814-820.
104. Ruiu S, Pinna GA, Marchese G, Mussinu JM, Saba P, Tambaro S, Casti P, Vargiu R & Pani L 2003 Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. Journal of Pharmacology and Experimental Therapeutics 306 363-370.
105. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T & Greasley PJ 2007 The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology 152 1092-1101.
106. Sarnataro D, Pisanti S, Santoro A, Gazzerro P, Malfitano AM, Laezza C & Bifulco M 2006 The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Molecular Pharmacology 70 1298-1306.
107. Savinainen JR, Saario SM, Niemi R, Jarvinen T & Laitinen JT 2003 An optimized approach to study endocannabinoid signalling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. British Journal of Pharmacology 140 1451-1459.
108. Seifert R & Wenzel-Seifert K 2002 Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn-Schmiedeberg's Archives of Pharmacology 366 381-416.
109. 35S]GTPgammaS autoradiography in rat brain. Journal of Neuroscience 16 8057-8066.
110. Steinberg BA & Cannon CP 2007 Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential. American Journal of Cardiology 100 27P-32P.
111. Straiker A, Stella N, Piomelli D, Mackie K, Karten HJ &Maguire G 1999 Cannabinoid CB1 receptors and ligands in vertebrate retina: localization and function of an endogenous signalling system. PNAS 96 14565-14570.
112. 2+ in neuroblastoma X glioma hybrid NG108-15 cells. Biochemical and Biophysical Research Communications 229 58-64.
113. 2+ transient in NG108-15 cells Journal of Biochemistry 122 890-895.
114. Sugiura T, Kishimoto S, Oka S & Gokoh M 2006 Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Progress in Lipid Research 45 405-446.
115. Szidonya L, Cserzo M & Hunyady L 2008 Dimerization and oligomerization of G-protein-coupled receptors: debated structures with established and emerging functions. Journal of Endocrinology 196 435-453.
116. Turu G, Simon A, Gyombolai P, Szidonya L, Bagdy G, Lenkei Z & Hunyady L 2007 The role of diacylglycerol lipase in constitutive and angiotensin AT1 receptor-stimulated cannabinoid CB1 receptor activity. Journal of Biological Chemistry 282 7753-7757.
117. Turu G, Varnai P, Gyombolai P, Szidonya L, Offertaler L, Bagdy G, Kunos G & Hunyady L 2009 Paracrine transactivation of the CB1 cannabinoid receptor by AT1 angiotensin and other Gq/11 proteincoupled receptors. Journal of Biological Chemistry 284 16914-16921.
118. Vasquez C & Lewis DL 1999 The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. Journal of Neuroscience 19 9271-9280.
119. Wager-Miller J, Westenbroek R & Mackie K 2002 Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example. Chemistry and Physics of Lipids 121 83-89.
120. 2+ signalling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. Journal of Cell Science 121 1704-1717.
121. Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, Kostenis E, Portoghese PS & Whistler JL 2005 A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. PNAS 102 9050-9055.
122. Wilson RI & Nicoll RA 2001 Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410 588-592.
123. Yin H, Chu A, Li W, Wang B, Shelton F, Otero F, Nguyen DG, Caldwell JS & Chen YA 2009 Lipid G protein-coupled receptor ligand identification using β-arrestin PathHunter assay. Journal of Biological Chemistry 284 12328-12338.
124. Zhu PJ & Lovinger DM 2005 Retrograde endocannabinoid signalling in a postsynaptic neuron/synaptic bouton preparation from basolateral amygdala. Journal of Neuroscience 25 6199-6207.